BACKGROUND: Imatinib mesylate blocks the tyrosine kinase activity of KIT (CD117) and is an effective treatment for gastrointestinal stromal tumors. In multiple myeloma, KIT expression has been detected by flow cytometry in about 33% of specimens, but no previous immunohistochemical assessment has yet been made of the expression pattern of KIT. MATERIALS AND METHODS: We performed immunohistochemical analyses of 100 patients, including 72 with multiple myeloma (MM), 8 with lymphoplasmacytic lymphoma (LPL), 10 with monoclonal gammopathy of undetermined significance (MGUS) and 10 with reactive plasmocytosis. One KIT-positive MM was sequenced using polymerase chain reaction analysis. RESULTS: In MM, only 2 cases (2.8%) were KIT positive. The great majority of the cases (97, 2%) did not express the KIT receptor tyrosine kinase. No mutation of the c-kit gene was detected. CONCLUSIONS: KIT expression is a rare event in MM and not detectable in MGUS and LPL. Therefore, treatment with imatinib is unlikely to be effective in these patients.
BACKGROUND:Imatinib mesylate blocks the tyrosine kinase activity of KIT (CD117) and is an effective treatment for gastrointestinal stromal tumors. In multiple myeloma, KIT expression has been detected by flow cytometry in about 33% of specimens, but no previous immunohistochemical assessment has yet been made of the expression pattern of KIT. MATERIALS AND METHODS: We performed immunohistochemical analyses of 100 patients, including 72 with multiple myeloma (MM), 8 with lymphoplasmacytic lymphoma (LPL), 10 with monoclonal gammopathy of undetermined significance (MGUS) and 10 with reactive plasmocytosis. One KIT-positive MM was sequenced using polymerase chain reaction analysis. RESULTS: In MM, only 2 cases (2.8%) were KIT positive. The great majority of the cases (97, 2%) did not express the KITreceptor tyrosine kinase. No mutation of the c-kit gene was detected. CONCLUSIONS:KIT expression is a rare event in MM and not detectable in MGUS and LPL. Therefore, treatment with imatinib is unlikely to be effective in these patients.
Authors: Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: J Almeida; A Orfao; M Ocqueteau; G Mateo; M Corral; M D Caballero; J Blade; M J Moro; J Hernandez; J F San Miguel Journal: Br J Haematol Date: 1999-10 Impact factor: 6.998
Authors: M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; D Caballero; M Rozman; J F San Miguel Journal: Am J Pathol Date: 1998-06 Impact factor: 4.307
Authors: Brian P Rubin; Scott M Schuetze; Janet F Eary; Thomas H Norwood; Sohail Mirza; Ernest U Conrad; James D Bruckner Journal: J Clin Oncol Date: 2002-09-01 Impact factor: 44.544
Authors: R García-Sanz; A Orfão; M González; M D Tabernero; J Bladé; M J Moro; J Fernández-Calvo; M A Sanz; J A Pérez-Simón; A Rasillo; J F Miguel Journal: Blood Date: 1999-02-01 Impact factor: 22.113
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Michael Medinger; Manuela Kleinschmidt; Klaus Mross; Barbara Wehmeyer; Clemens Unger; Hans-Eckart Schaefer; Renate Weber; Marc Azemar Journal: Pathol Oncol Res Date: 2010-02-23 Impact factor: 3.201